ADMS News and Press, Adamas Pharmaceuticals Inc. From 11/05/20

Third quarter 2020 total revenues of $20.2 million, a 45% increase over third quarter 2019 Third quarter 2020 GOCOVRI® product sales of $19.0 million, a 36% increase over third quarter 2019 Total paid prescriptions of 7,930, a 19% increase over third quarter 2019 ...

EMERYVILLE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 third quarter financial results on Thursday, November 5, 2020, after market close. Subsequently, Adamas’ management team will host a con...

Adamas Pharmaceuticals ([[ADMS]] +0.8%) has appointed Adrian Quartel as Chief Medical Officer. He brings over 20 years of experience, and most recently, he was the global head of Medical Affairs at BioMarin. For further details see: Adamas Pharma names new CMO

EMERYVILLE, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Adrian Quartel, MD a...

Gainers: American Well (AMWL) +17%, MediciNova (MNOV) +13%, Mallinckrodt (MNK) +7%, Capricor Therapeutics (CAPR) +8%, Adamas Pharmaceuticals (ADMS) +6%.Losers: AC Immune (ACIU) -42%, Wave Life Sciences (WVE) -34%, Rockwell Medical (RMTI)&...

EMERYVILLE, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVRI ® (...

EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company&#...

Adamas Pharmaceuticals (ADMS) recently reported their Q2 earnings with a substantial beat on both EPS and revenue despite an ongoing pandemic. The market did respond appropriately, with the stock trading up nearly 50% following the press release. Unfortunately, the stock is still down over...

Gainers:  Seres Therapeutics (NASDAQ: MCRB ) +356% . More news on: Seres Therapeutics, Inc., Xtant Medical Holdings, Inc., BiomX Inc., Stocks on the move, , Read more ...

The following slide deck was published by Adamas Pharmaceuticals, Inc. in conjunction with their 2020 Q2 earnings Read more ...